Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of anti-osteoporosis treatment for men with osteoporosis: a meta-analysis

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

Introduction

Osteoporosis and fracture are important healthcare problems for men worldwide, which are relevant to severe disability and mortality. This meta-analysis aimed to assess the effectiveness of pharmacological therapy in men with osteoporosis, and to provide evidence-based hints for clinical practice.

Materials and Methods

PubMed, Embase, Web of Science were searched from inception to July 31, 2022. Pooled standardized mean difference (SMD) and relative risk (RR) were calculated. Heterogeneity between included studies and publication bias were detected.

Results

Twenty clinical studies were enrolled in this meta-analysis. The pooled SMD for mean percentage differences of change from baseline in lumbar spine BMD between the treatment group and the control group was 4.95 (95% CI 2.48, 7.42, I2 = 99%, p < 0.0001). For mean percentage differences of change in femoral neck BMD, the overall SMD was 3.08 (95% CI 0.95, 5.20, I2 = 99%, p = 0.0045). For a change in total hip BMD, the overall SMD was 1.06 (95% CI 0.50, 1.63, I2 = 82%, p = 0.0002). The overall RR for incident vertebral fractures was 0.50 (95% CI 0.37, 0.68, I2 = 5%, p = 0.3971). The pooled RR for nonvertebral fractures and clinical fracture were 0.74 (95% CI 0.41, 1.33, I2 = 28%, p = 0.3139) and 0.81 (95% CI 0.54, 1.21, I2 = 0%, p = 0.2992).

Conclusion

Findings in this meta-analysis indicate that pharmacological treatment increases lumbar spine, femoral neck, total hip BMD, and decreases incident vertebral fractures in men with osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data avalibality

All data generated or analysed during this study are included in this published article [and its supplementary information files].

References

  1. Rinonapoli G, Ruggiero C, Meccariello L, Bisaccia M, Ceccarini P, Caraffa A (2021) Osteoporosis in men: a review of an underestimated bone condition. Int J Mol Sci 22:2105

    Article  PubMed  PubMed Central  Google Scholar 

  2. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N (2008) A reference standard for the description of osteoporosis. Bone 42:467–475

    Article  CAS  PubMed  Google Scholar 

  3. Ioannidis G, Papaioannou A, Hopman WM, Akhtar-Danesh N, Anastassiades T, Pickard L, Kennedy CC, Prior JC, Olszynski WP, Davison KS, Goltzman D, Thabane L, Gafni A, Papadimitropoulos EA, Brown JP, Josse RG, Hanley DA, Adachi JD (2009) Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. Can Med Assoc J 181:265

    Article  Google Scholar 

  4. Bliuc D, Nguyen ND, Nguyen TV, Eisman JA, Center JR (2013) Compound risk of high mortality following osteoporotic fracture and refracture in elderly women and men. J Bone Miner Res 28:2317–2324

    Article  PubMed  Google Scholar 

  5. Vilaca T, Eastell R, Schini M (2022) Osteoporosis in men. Lancet Diabet Endocrinol 10:273–283

    Article  Google Scholar 

  6. Johnell O, Kanis J (2005) Epidemiology of osteoporotic fractures. Osteoporos Int 16:S3-7

    Article  PubMed  Google Scholar 

  7. Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733

    Article  CAS  PubMed  Google Scholar 

  8. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB (2009) Incidence and mortality of hip fractures in the United States. JAMA 302:1573–1579

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Gennari L, Bilezikian JP (2007) Osteoporosis in Men. Endocrinol Metab Clin North Am 36:399–419

    Article  CAS  PubMed  Google Scholar 

  10. Willson T, Nelson SD, Newbold J, Nelson RE, LaFleur J (2015) The clinical epidemiology of male osteoporosis: a review of the recent literature. Clin Epidemiol 7:65–76

    PubMed  PubMed Central  Google Scholar 

  11. Khosla S, Amin S, Orwoll E (2008) Osteoporosis in men. Endocr Rev 29:441–464

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Vescini F, Chiodini I, Falchetti A, Palermo A, Salcuni AS, Bonadonna S, De Geronimo V, Cesareo R, Giovanelli L, Brigo M, Bertoldo F, Scillitani A, Gennari L (2021) Management of Osteoporosis in Men: A Narrative Review. Int J Mol Sci 22:13640

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Gennari L, Bilezikian JP (2018) New and developing pharmacotherapy for osteoporosis in men. Expert Opin Pharmacother 19:253–264

    Article  CAS  PubMed  Google Scholar 

  14. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fract Inter Trial Res Group Lancet 348:1535–1541

    CAS  Google Scholar 

  15. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604–610

    Article  CAS  PubMed  Google Scholar 

  16. Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J et al (2012) Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 367:1714–1723

    Article  CAS  PubMed  Google Scholar 

  17. Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD (2009) Once-weekly risedronate in men with osteoporosis: Results of a 2-Year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 24:719–725

    Article  CAS  PubMed  Google Scholar 

  18. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745–755

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA (2003) The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9–17

    Article  CAS  PubMed  Google Scholar 

  20. Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, Lindsay R, Mitlak BH (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 16:510–516

    Article  CAS  PubMed  Google Scholar 

  21. Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, Miyauchi A, Maddox J, Chen L, Horlait S (2018) A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. J Clin Endocrinol Metab 103:3183–3193

    Article  PubMed  Google Scholar 

  22. Moher D, Liberati A, Tetzlaff J, Altman DG (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8:336–341

    Article  PubMed  Google Scholar 

  23. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928

    Article  PubMed  PubMed Central  Google Scholar 

  24. Riley RD, Gates S, Neilson J, Alfirevic Z (2011) Statistical methods can be improved within Cochrane pregnancy and childbirth reviews. J Clin Epidemiol 64:608–618

    Article  PubMed  Google Scholar 

  25. Borenstein M, Hedges LV, Higgins JP, Rothstein HR (2010) A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Method 1:97–111

    Article  Google Scholar 

  26. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Binkley N, Orwoll E, Chapurlat R, Langdahl BL, Scott BB, Giezek H, Santora AC (2021) Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis. Osteoporos Int 32:173–184

    Article  CAS  PubMed  Google Scholar 

  28. Boonen S, Lorenc RS, Wenderoth D, Stoner KJ, Eusebio R, Orwoll ES (2012) Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study. Bone 51:383–388

    Article  CAS  PubMed  Google Scholar 

  29. Boonen S, Orwoll E, Magaziner J, Colón-Emeric CS, Adachi JD, Bucci-Rechtweg C, Haentjens P, Kaufman JM, Rizzoli R, Vanderschueren D, Claessens F, Sermon A, Witvrouw R, Milisen K, Su G, Lyles KW (2011) Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc 59:2084–2090

    Article  PubMed  Google Scholar 

  30. Ebeling PR, Wark JD, Yeung S, Poon C, Salehi N, Nicholson GC, Kotowicz MA (2001) Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: A two-year randomized, double blind, double placebo study. J Clin Endocrinol Metab 86:4098–4103

    Article  CAS  PubMed  Google Scholar 

  31. Hwang JS, Liou MJ, Ho C, Lin JD, Huang YY, Wang CJ, Tsai KS, Chen JF (2010) The effects of weekly alendronate therapy in Taiwanese males with osteoporosis. J Bone Miner Metab 28:328–333

    Article  CAS  PubMed  Google Scholar 

  32. Kachnic LA, Pugh SL, Tai P, Smith M, Gore E, Shah AB, Martin AG, Kim HE, Nabid A, Lawton CA (2013) RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients. Prostate Cancer Prostatic Dis 16:382–386

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Kaufman JM, Audran M, Bianchi G, Braga V, Diaz-Curiel M, Francis RM, Goemaere S, Josse R, Palacios S, Ringe JD, Felsenberg D, Boonen S (2013) Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab 98:592–601

    Article  CAS  PubMed  Google Scholar 

  34. Miller PD, Schnitzer T, Emkey R, Orwoll E, Rosen C, Ettinger M, Vandormael K, Daifotis A (2004) Weekly oral alendronic acid in male osteoporosis. Clin Drug Investig 24:333–341

    Article  CAS  PubMed  Google Scholar 

  35. Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Shiraki M, Fukunaga M (2014) Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab 99:2599–2607

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Orwoll E, Teglbjrg CS, Langdahl BL, Chapurlat R, Czerwinski E et al (2012) A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density. J Clin Endocrinol Metab 97:3161–3169

    Article  CAS  PubMed  Google Scholar 

  37. Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G (2010) Efficacy and safety of monthly ibandronate in men with low bone density. Bone 46:970–976

    Article  CAS  PubMed  Google Scholar 

  38. Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS (2010) Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 25:2239–2250

    Article  CAS  PubMed  Google Scholar 

  39. Ringe JD, Dorst A, Faber H, Ibach K (2004) Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 24:110–113

    Article  CAS  PubMed  Google Scholar 

  40. Ringe JD, Farahmand P, Faber H, Dorst A (2009) Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. Rheumatol Int 29:311–315

    Article  CAS  PubMed  Google Scholar 

  41. Toth E, Csupor E, Meszaros S, Ferencz V, Nemeth L, McCloskey EV, Horvath C (2005) The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures–an open label study. Bone 36:47–51

    Article  CAS  PubMed  Google Scholar 

  42. Trovas GP, Lyritis GP, Galanos A, Raptou P, Constantelou E (2002) A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res 17:521–527

    Article  CAS  PubMed  Google Scholar 

  43. Sidlauskas KM, Sutton EE, Biddle MA (2014) Osteoporosis in men: epidemiology and treatment with denosumab. Clin Interv Aging 9:593–601

    PubMed  PubMed Central  Google Scholar 

  44. Zhong ZM, Chen JT (2009) Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials. Clin Drug Investig 29:349–357

    Article  CAS  PubMed  Google Scholar 

  45. Xu Z (2017) Alendronate for the Treatment of Osteoporosis in Men: A Meta-Analysis of Randomized Controlled Trials. Am J Ther 24:e130–e138

    Article  PubMed  Google Scholar 

  46. Nayak S, Greenspan SL (2017) Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis. J Am Geriatr Soc 65:490–495

    Article  PubMed  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Department of Endocrinology, Peking University First Hospital, Beijing, 100034, China

    Aimei Dong & Youyuan Huang

  2. Department of Emergency Department, Peking University First Hospital, Beijing, 100034, China

    Xiuwen Fei

  3. Department of General Practice, Peking University First Hospital, Beijing, 100034, China

    Yucheng Huang

Authors
  1. Aimei Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiuwen Fei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yucheng Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Youyuan Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AD and XF carried out the studies, participated in collecting data, and drafted the manuscript. AD and YH performed the statistical analysis and participated in its design. YH and YH participated in the acquisition, analysis, or interpretation of data. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Aimei Dong.

Ethics declarations

Conflict of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Ethical approval

Not applicable.

Informed consent

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 19 KB)

774_2023_1407_MOESM2_ESM.tiff

Supplementary file2 Figure S1. Forest plots of percentage change in lumbar spine BMD for bisphosphonates and non-bisphosphonates groups. (TIFF 85 KB)

774_2023_1407_MOESM3_ESM.tiff

Supplementary file3 Figure S2. Forest plots of percentage change in femoral neck BMD for bisphosphonates and non-bisphosphonates groups. (TIFF 85 KB)

Supplementary file4 Figure S3. Forest plots of percentage change in total hip BMD. (TIF 130 KB)

774_2023_1407_MOESM5_ESM.tif

Supplementary file5 Figure S4. Forest plots of percentage change in total hip BMD for bisphosphonates and non-bisphosphonates groups. (TIF 132 KB)

774_2023_1407_MOESM6_ESM.tiff

Supplementary file6 Figure S5. Forest plots of RR for incident vertebral fractures for bisphosphonates and non-bisphosphonates groups. (TIFF 141 KB)

Supplementary file7 Figure S6. Forest plots of RR for incident nonvertebral fractures. (TIF 139 KB)

774_2023_1407_MOESM8_ESM.tif

Supplementary file8 Figure S7. Forest plots of RR for incident nonvertebral fractures for bisphosphonates and non-bisphosphonates groups. (TIF 155 KB)

Supplementary file9 Figure S8. Forest plots of RR for incident clinical fractures. (TIF 143 KB)

774_2023_1407_MOESM10_ESM.tif

Supplementary file10 Figure S9. Forest plots of RR for incident clinical fractures for bisphosphonates and non-bisphosphonates groups. (TIF 159 KB)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dong, A., Fei, X., Huang, Y. et al. Efficacy of anti-osteoporosis treatment for men with osteoporosis: a meta-analysis. J Bone Miner Metab 41, 258–267 (2023). https://doi.org/10.1007/s00774-023-01407-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-023-01407-0

Keywords

Search

Navigation